Schwarz 2010.

Methods	Randomised, open‐label trial
Participants	Number; 107 participants 54 received nadroparin and 53 received compression therapy Age (mean ± SD years): 54 ± 15, nadroparin group; 57 ± 14, compression therapy group Gender (M/F): 24/30, nadroparin group; 15/38, compression therapy group
Interventions	Nadroparin for 10 days vs no anticoagulation Intervention: 180 antiXa u/kg nadroparin once daily for 10 days plus compression therapy with graduated class‐II‐calf stockings for 3 months. Control: compression therapy alone with graduated class‐II‐calf stockings for 3 months.
Outcomes	Progression into the deep veins and clinical PE
Notes	People with previous VTE were excluded. Funding/support; "Supported by Sanofi Synthelabo, Berlin, Germany."
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation table.
Allocation concealment (selection bias)	Unclear risk	Insufficient information about allocation concealment.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	No blinding of outcome assessment but the review authors judged that the outcome measurement was unlikely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data.
Selective reporting (reporting bias)	Low risk	Published report included all expected outcomes.
Other bias	Low risk	Study appeared free of other sources of bias.

APTT: activated partial thromboplastin time; DVT: deep vein thrombosis; F: female; INR: international normalised ratio; IQR: interquartile range; LMWH: low molecular weight heparin; M: male; PE: pulmonary embolism; PTS: post‐thrombotic syndrome; SD: standard deviation; UFH: unfractionated heparin; VKA: vitamin K antagonist; VTE: venous thromboembolism.